Dr. Jing Chen: A Pioneer in Pediatric Hematology and Oncology

As a renowned expert in pediatric hematology and oncology, Dr. Jing Chen has dedicated her career to advancing the field through groundbreaking research and innovative treatments. With over 150 publications, including first or corresponding authorship on articles like 'Cancer Cell,' and five monographs as chief editor or vice editor, Dr. Chen is a respected authority in her field.

Dr. Chen's impressive bibliography includes numerous funded protocols from the National Nature and Science Foundation and Shanghai Municipal Committee of Science and Technology. Her work has been recognized with several prestigious awards, including the China Anti-Cancer Association Science and Technology Award, HuaXia Medicine Award, and Soong Ching Ling Pediatric Medicine Award.

As the head of the Hematology group at the Shanghai branch of Chinese Medical Association, Dr. Chen plays a vital role in shaping the direction of pediatric hematology research in China. Her expertise extends to her position as Director of China Hematology/Oncology Pediatric Alliance (CHOPA), National Children's Medical Center, and Deputy Head of Hematology group of Committee of Chinese Medical Association.

Dr. Chen's clinical focus lies in hematopoietic stem cell transplantation for pediatric patients with severe aplastic anemia, congenital rare diseases, and bone marrow failure syndromes. Her work has been instrumental in the development of pediatric HCT in China, and she is a leading figure in the field of pediatric hematology.

Dr. Chen's academic background is impressive, having received her MD/PhD degree from Shanghai JiaoTong University School of Medicine in 2019. She has also undergone training at prestigious institutions such as MD Anderson and Memorial Sloan-Kettering Cancer Center.

In addition to her numerous publications and awards, Dr. Chen is currently leading a multi-center clinical trial on first-line alternate donor HCT for children with severe aplastic anemia and organizing a multicenter, prospective study on TCRαβ Depleted Haploidentical Transplant and risk-adapted therapy for juvenile myelomonocytic leukemia (JMML) in China.

With her extensive experience, impressive credentials, and commitment to advancing pediatric hematology and oncology research, Dr. Jing Chen is an inspiration to her peers and a driving force behind the development of innovative treatments for children with life-threatening diseases.

Jing chen md